Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
CLINICAL LABORATORY IMMUNOLOGY

National Prevalence Estimates for Cytomegalovirus IgM and IgG Avidity and Association between High IgM Antibody Titer and Low IgG Avidity

Sheila C. Dollard, Stephanie A. S. Staras, Minal M. Amin, D. Scott Schmid, Michael J. Cannon
Sheila C. Dollard
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: SDollard@cdc.gov
Stephanie A. S. Staras
The University of Florida, Department of Health Outcomes and Policy, Gainesville, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minal M. Amin
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Scott Schmid
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Cannon
Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CVI.05228-11
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Relationship between CMV IgM antibody levels measured by UA/ml and endpoint antibody titer. Twofold serial dilutions were performed on six IgM-positive sera from the NHANES collection. UA/ml decreases approximately linearly with dilution. Sera with higher initial UA/ml values have higher endpoint titers, shown by enlarged black diamonds. The Vidas test cutoff for IgM positivity is 0.90 UA/ml.

  • Fig. 2.
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Association between CMV IgM antibody levels and CMV IgG avidity. CMV IgM-negative (white), IgM-equivocal (gray), and IgM-positive (black) serum specimens are plotted according to their IgM antibody level measured by UA/ml and their IgG avidity index. The assay cutoff for IgM positivity is 0.9 UA/ml. The avidity test cutoff used for this analysis was 0.7, marked by the dashed line.

Tables

  • Figures
  • Table 1.

    CMV IgG and IgM prevalence estimates (weighted) by age among 5,992 women from the NHANES national surveya

    Age of women (yr)No. tested% positive for:
    CMV IgGCMV IgM
    12–191,52547.32.6
    20–291,64354.44.5
    30–391,61659.72.3
    40–491,20869.82.4
    Total5,99257.93.0
    • ↵a Three of the IgM+ sera were IgG−; the rest were IgG+.

  • Table 2.

    Prevalence estimates (weighted) for CMV IgG low avidity by age among the 126 IgM+ sera from the NHANES national survey

    Age of women (yr)No. testedMedian % positive (95% CI) by test cutoff for low aviditya
    0.80.70.6
    12–193667.4 (35.3–88.6)33.0 (11.6–64.9)12.3 (2.9–40.1)
    20–295230.7 (16.8–49.1)16.5 (7.1–33.8)10.4 (3.8–25.6)
    30–493817.1 (7.1–35.7)3.1 (0.6–14.0)3.1 (0.6–14.0)
    All ages12631.1 (20.1–44.6)13.5 (6.1–27.5)7.6 (3.5–15.9)
    • ↵a P values for trends with age were 0.004, 0.048, and 0.3 for cutoff values of 0.8, 0.7, and 0.6, respectively. 95% CI, 95% confidence intervals.

  • Table 3.

    Low-CMV-IgG-avidity prevalence estimates (unweighted) for both CMV IgM-positive and IgM-negative sera from the NHANES survey, according to avidity test cutoff

    CMV IgM status (no. tested)% prevalence of low IgG avidity (no. of specimens) by avidity test cutoff
    0.800.700.60
    IgM+ (126)34.9 (44)18.3 (23)11.1 (14)
    IgM− (129)8.5 (11)2.3 (3)0.8 (1)
    IgM+ and IgM− combined (255)6.6 (55)2.0 (26)0.8 (15)
  • Table 4.

    Association between CMV IgM antibody level and low IgG aviditya

    IgM UA/mlNo. of sera (total = 324)% low avidity
    IgM negative or equivalent, <0.901541.9
    0.90–1.09506.0
    1.10–1.292615.4
    1.30–1.492917.2
    1.50–1.993240.6
    ≥2.00–4.003378.8
    • ↵a Sera are listed by increasing levels of IgM antibody, showing the proportion that were low IgG avidity. Chi-square test for trend, P < 0.0001. The 0.7 avidity test cutoff was used to define low IgG avidity.

PreviousNext
Back to top
Download PDF
Citation Tools
National Prevalence Estimates for Cytomegalovirus IgM and IgG Avidity and Association between High IgM Antibody Titer and Low IgG Avidity
Sheila C. Dollard, Stephanie A. S. Staras, Minal M. Amin, D. Scott Schmid, Michael J. Cannon
Clinical and Vaccine Immunology Nov 2011, 18 (11) 1895-1899; DOI: 10.1128/CVI.05228-11

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
National Prevalence Estimates for Cytomegalovirus IgM and IgG Avidity and Association between High IgM Antibody Titer and Low IgG Avidity
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
Share
National Prevalence Estimates for Cytomegalovirus IgM and IgG Avidity and Association between High IgM Antibody Titer and Low IgG Avidity
Sheila C. Dollard, Stephanie A. S. Staras, Minal M. Amin, D. Scott Schmid, Michael J. Cannon
Clinical and Vaccine Immunology Nov 2011, 18 (11) 1895-1899; DOI: 10.1128/CVI.05228-11
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X